Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04314401 | National Cancer Institute "Cancer Moonshot Biobank" | active not recruiting | — | 1,600 | National Cancer Institute (NCI)NIH | 2 | May 13, 2026 | clinicaltrials |
| NCT05002816 | Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 24 | Yale UniversityOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05497804 | Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial | active not recruiting | Phase 2 | 17 | Mayo ClinicOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05514990 | Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial | active not recruiting | Phase 1 / Phase 2 | 10 | University of Southern CaliforniaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05981209 | Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies | active not recruiting | Phase 1 | 12 | Abdullah KhanOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06385496 | Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT06390865 | Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) | active not recruiting | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT06400225 | Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT06504199 | Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma(ZGR) | active not recruiting | Phase 2 | 39 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT01703949 | Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma | active not recruiting | Phase 2 | 28 | University of WashingtonOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03038672 | Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas | active not recruiting | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | May 12, 2026 | clinicaltrials |
| NCT04263480 | Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia(CZAR-1) | active not recruiting | Phase 2 | 99 | Christian BuskeOTHER | 3 | May 12, 2026 | clinicaltrials |
| NCT00871013 | Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy | active not recruiting | Phase 2 | 160 | University of ArkansasOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04273139 | Ibrutinib + Venetoclax in Untreated WM | active not recruiting | Phase 2 | 45 | Dana-Farber Cancer InstituteOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05060627 | Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide | active not recruiting | Phase 1 / Phase 2 | 60 | PETHEMA FoundationOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05688475 | A Rollover Study of CC-122 | active not recruiting | Phase 1 | 12 | Bristol-Myers SquibbINDUSTRY | 4 | May 11, 2026 | clinicaltrials |
| NCT06230224 | A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma(OLYMPIA-4) | active not recruiting | Phase 3 | 216 | Regeneron PharmaceuticalsINDUSTRY | 14 | May 11, 2026 | clinicaltrials |
| NCT04439110 | Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q) | active not recruiting | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | May 8, 2026 | clinicaltrials |
| NCT05527340 | Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients. | active not recruiting | Phase 2 | 140 | PETHEMA FoundationOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05718869 | Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study | active not recruiting | Phase 2 | 26 | City of Hope Medical CenterOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04439266 | Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F) | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | May 7, 2026 | clinicaltrials |
| NCT04439279 | Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 7, 2026 | clinicaltrials |
| NCT04439331 | Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 7, 2026 | clinicaltrials |
| NCT04439344 | Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) | active not recruiting | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | May 7, 2026 | clinicaltrials |
| NCT06014762 | P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | active not recruiting | Phase 1 | 120 | Poseida Therapeutics, Inc.INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT03322865 | Obinutuzumab in Marginal Zone Lymphoma | active not recruiting | Phase 2 | 56 | Christian BuskeOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03474744 | Copanlisib and Rituximab in Marginal Zone Lymphoma Patients | active not recruiting | Phase 2 | 36 | Christian BuskeOTHER | 2 | May 6, 2026 | clinicaltrials |
| NCT04126200 | Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)(DREAMM 5) | active not recruiting | Phase 1 / Phase 2 | 208 | GlaxoSmithKlineINDUSTRY | 13 | May 6, 2026 | clinicaltrials |
| NCT04439123 | Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 6, 2026 | clinicaltrials |
| NCT04439175 | Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) | active not recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | May 6, 2026 | clinicaltrials |
| NCT07084896 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 106 | GlaxoSmithKlineINDUSTRY | 13 | May 6, 2026 | clinicaltrials |
| NCT01177527 | Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders | active not recruiting | — | 656 | Dana-Farber Cancer InstituteOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT02029443 | ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia | active not recruiting | Phase 1 / Phase 2 | 306 | Acerta Pharma BVINDUSTRY | 3 | May 5, 2026 | clinicaltrials |
| NCT04978584 | Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study | active not recruiting | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05400109 | Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas | active not recruiting | Phase 1 | 21 | David WaldOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05429268 | Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)(firmMIND) | active not recruiting | Phase 3 | 82 | Incyte CorporationINDUSTRY | 14 | May 5, 2026 | clinicaltrials |
| NCT05490771 | Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 5, 2026 | clinicaltrials |
| NCT07226752 | A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China | active not recruiting | Phase 3 | 72 | GenmabINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT03319667 | A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant(IMROZ) | active not recruiting | Phase 3 | 475 | SanofiINDUSTRY | 21 | May 4, 2026 | clinicaltrials |
| NCT05618028 | Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets | active not recruiting | Phase 1 | 78 | AbbVieINDUSTRY | 10 | May 4, 2026 | clinicaltrials |
| NCT03913949 | A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies | active not recruiting | Phase 1 | 74 | Ascentage Pharma Group Inc.INDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT06362148 | Circulating Tumor DNA in Peripheral T-cell Lymphomas(CIRCULATE) | active not recruiting | — | 50 | University of AarhusOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT03206671 | Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents(B-NHL 2013) | active not recruiting | Phase 3 | 650 | University Hospital MuensterOTHER | 8 | Apr 30, 2026 | clinicaltrials |
| NCT04546620 | Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)(REMoDL-A) | active not recruiting | Phase 2 | 453 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04653246 | Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM | active not recruiting | Phase 2 | 52 | Jacob Laubach, MDOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05014646 | Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients | active not recruiting | Phase 2 | 27 | City of Hope Medical CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05889221 | Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma | active not recruiting | N/A | 74 | Poitiers University HospitalOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT01500733 | PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 86 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Apr 28, 2026 | clinicaltrials |
| NCT02732275 | DS-3201b in Participants With Lymphomas | active not recruiting | Phase 1 | 100 | Daiichi Sankyo Co., Ltd.INDUSTRY | 2 | Apr 28, 2026 | clinicaltrials |
| NCT02911571 | PRospective Multiple Myeloma Impact Study(PROMMIS) | active not recruiting | N/A | 250 | SkylineDxINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 13, 2026source: clinicaltrials